心房颤动:流行病学、风险与管理要点
wearable设备等可提高房颤检出率,房颤增加卒中、心衰及死亡风险。 各大指南提倡以卒中预防、症状缓解、危险因素管理为核心的综合管理模式。
要点
- 房颤增加卒中、血栓栓塞、心衰和死亡风险,并与生活质量下降相关。
- 多数房颤患者默认应使用口服抗凝药预防卒中。
- 导管消融术近期被重新考虑作为缓解症状的初始治疗选择。
核心结论
- 房颤管理需纳入卒中预防、症状控制、危险因素识别与优化,并采用多学科参与的综合管理模式。
研究设计与样本
- 来源类型为pubmed(Lancet),内容为心房颤动专题综述或指南性总结,未报告具体研究设计与样本量。
主要发现
- 内置诊断算法的可穿戴设备等使公众房颤检出率较前增加。
- 房颤患者常合并多种疾病,年龄增长和生活方式等危险因素累积增加管理复杂性。
关键数值与推荐
- 所有主要临床指南均倡导将卒中预防、症状缓解、危险因素识别与管理及多学科支持作为房颤管理基本要素。
- 口服抗凝药仍是多数房颤患者预防卒中的默认治疗。
- 导管消融术近期被重新考虑作为缓解症状的初始治疗选择。
临床怎么用
- 对多数房颤患者应默认采用口服抗凝药预防卒中。
- 可通过以患者为中心的管理和提升健康素养,鼓励患者主动参与房颤管理。
- 对新出现及已有的危险因素应早期识别并适当管理,以优化房颤照护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atrial fibrillation affects approximately 37·6 million people worldwide, with the prevalence predicted to double over the next 35 years. The ubiquitous use of wearable devices and other technologies with inbuilt diagnostic algorithms allows greater detection of atrial fibrillation among the general public than previously. Atrial fibrillation increases the risk of stroke and thromboembolism, heart failure, and death, and is associated with reductions in quality of life. Patients with atrial fibrillation frequently have comorbidities, and the accumulation of risk factors, including lifestyle factors associated with poorer health outcomes, and increasing age, often adds to the complexity of managing such patients. All major clinical guidelines advocate that stroke prevention, symptom relief, identification of risk factors, and optimisation of risk factor management, incorporated into an integrated care approach, with multidisciplinary input as required, are essential elements of atrial fibrillation management. Avoidance of stroke with oral anticoagulation remains the default for most patients with atrial fibrillation and, more recently, catheter ablation has been reconsidered as an initial treatment option for symptom relief. The dynamic nature of risk factors requires early identification and appropriate management of new and existing risk factors to optimise atrial fibrillation care. Patient-centred care and better health literacy can empower patients to take a more active role in their atrial fibrillation management.
引用
- Lane, Andrade, Arbelo, et al. Atrial fibrillation. Lancet. 2026. PMID: 41794418. doi:10.1016/S0140-6736(25)02166-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。